Table 2b.

Selected randomized cetuximab studies in patients with KRAS wild-type metastatic colorectal cancer

Author, year	Regimen	No of patients	RR (%)	Median TTP (months)	Median OS (months)
Third-line therapy
Karapetis et al 200868	BSC	113	0	1.9	4.8
	Cet	117	11*	3.8*	9.5*
First-line therapy
Van Cutsem et al 200878	FOLFIRI	176	43	8.7	21.0
	FOLFIRI + Cet	172	59*	9.9*	24.9
Bokemeyer et al 200877	FOLFOX	73	37	7.2	–
	FOLFOX + Cet	61	61*	7.7*	–

^*Significant difference.

Abbreviations: Cet, cetuximab; Iri, irinotecan; BSC, best supportive care.